abbott post strong perform ceo mile white wind
updat forecast estim jan
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jan
estim jan
price data jan
rate updat jan
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
follow integr st jude medic abbott
continu improv profit segment nutrit
devic diagnost establish pharmaceut although
abbott made progress last seven year still lag
key rival profit measur despit compet
busi character attract margin
abbott effort improv effici includ streamlin
distribut channel build facil lower-cost locat
like china india demonstr success
still room improv look compani
consolid profit think abbott emphasi margin
improv pay next five year
like manag turn attent new sourc
growth view abbott freestyl libr blood glucos
monitor one compel innov firm ever
launch like abbott substanti footprint latin
america russia establish pharmaceut product
lead faster growth brand gener
addit st jude heart-focus portfolio along smaller
offer rais firm abil compet hospit client
seek winnow supplier
fuel
med-tech compani abbott big challeng
innov bar secur
reimburs new technolog risen payer
becom stringent clinic data commit
payment abbott seen recent success freestyl
libr less impress histor track record new
product launch compar key medic devic competitor
includ
abbott cultiv similar revolutionari advanc
firm fort seem focu around increment improv
exist technolog platform acquir last
year thank healthcar reform approach less like
yield robust return futur
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
analyst note ep calcul divid net incom averag number common
abbott manufactur market medic devic adult pediatr
nutrit product diagnost equip test kit brand
formula nutrit liquid adult immunoassay point-of-car
diagnost equip abbott deriv approxim sale outsid
unit state
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
increas fair valu estim per share
reflect expect robust top-lin
growth driven new product launch
remain optimist key growth driver
expect penetr larg underserv patient popul
continu expect top-lin strength domest
launch freestyl libr on-going adopt alin
system comprehens test panel point-of-car
diagnost innov structur heart heart
failur electrophysiolog neuromodul
area weak competitor
introduc new product segment return
growth expand salesforc gain
revenu growth fuel mitraclip
intern nutrit freestyl libr destin
therapi heartmat left ventricular assist devic
still see potenti improv profit abbott
remain busi turn key factor
valuat consolid basi abbott oper
margin significantli trail key competitor
variou busi segment good news abbott
compet sever market offer rel high
margin includ nutrit brand gener drug
cardiovascular devic addit abbott alreadi
begun effort improv product effici
streamlin distribut channel build new facil
lower-cost locat like china india expect
abbott partial close oper margin gap
project basi point improv
firm leverag distribut infrastructur
built penetr emerg market across
product segment extract cost synergi
abbott nutrit unit seem larg impervi
econom cycl think addit st jude increas
abbott exposur vagari cardiac product cycl
clinic trial reimburs issu accordingli
peg abbott uncertainti medium
bullish scenario put abbott valu per
share case assum abbott averag
top-lin growth thank addit st jude aler
well outsiz gain pediatr adult nutrit
intern double-digit growth structur heart
greater penetr cardiovascular devic oversea
also assum abbott reach level manufactur
expens compar key competitor like dr
reddi along oper margin
peak
bear case abbott per share
scenario top line averag annual howev
assum declin stent sale boston scientif
offer superior technolog long haul
mute perform mitraclip edward enter
domest market low-single-digit growth nutrit
low-single-digit growth diagnost assum
abbott rais oper margin
think addit st jude portfolio cardiac devic
push abbott toward wider side narrow moat
fulli convinc abbott tip
wide moat categori especi firm nurtur
kind on-going occasion revolutionari
innov necessari secur reimburs
longer term
case abbott one three four competitor
domin market includ nutrit cardiac
monitor coronari stent venou closur devic
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
build block experi nutrit
also play well appli abbott
establish pharmaceut product segment sold
outsid busi frequent call brand
gener oper like consum busi
gener mainli sold less develop market
often lack well-develop infrastructur distribut
instead abbott must sell product directli pharmaci
chain physician result brand recognit
reput key factor abbott leverag sell
fragment market also translat less price
pressur abbott could chang longer term
emerg market turn tender system
character develop nation howev chang
remain
cardiac
think abbott benefit consider addit
manag structur heart heart failur howev
juri still abbott abil nurtur renew
innov area long haul thu far abbott
done credibl job commerci alreadi
st jude pipelin less confid abbott
gener greater leap innov base track
record earlier acquisit
final abbott reli intellectu properti ward
competitor devic diagnost segment
think firm earn narrow moat four
segment translat narrow moat entir
potenti price pressur variou sourc
across abbott market exampl trend toward
brand gener declin
immunoassay market abbott particip
ration oligopoli enjoy benefit intang
think nutrit busi one moatiest
part abbott wield leadership posit
highli consolid market estim
billion world-wide asid strength develop
market firm face brighter growth prospect
emerg market growth middle-class
famili spur demand pediatr adult nutrit
product thank strong similac ensur brand
abbott advantag posit introduc new
formul line extens penetr new
market abbott made substanti invest earli
build infrastructur emerg market includ
new ventur new zealand-bas build
large-scal dairi farm hub china firm
reap reward invest expand
nutrit busi think agreement fonterra
may help abbott lower nutrit cost input china
believ substanti enough qualifi
moat sourc
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
reimburs vascular devic firm
invest pipelin lead stream new
product fortifi price power medium
term abbott scale divers help steadi moat
trend anticip strength coronari stent left
pharmaceut divis diabet busi
neuromodul molecular diagnost busi
off-set current weak
abbott abil deploy robust predict cash
flow
busi toward acquisit
partnership help replenish pipelin
support abbott growth also keep smaller
compani gain critic mass encroach
abbott narrow moat abbott develop
revolutionari devic pipelin candid demonstr
strongli favor clinic outcom acquir
extens collect med-tech product allow
comprehens partner hospit
consid turn moat trend rate posit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
oabbott xienc stent remain powerhous
well-
drug-elut stent market thank
establish record safeti efficaci
oearli result investig clinic trial
transcathet mitral valv
tendyn
favor pivot trial result favor
could give boost abbott structur heart unit
oabbott sale establish pharma busi
develop market acquisit
veropharm put abbott brand gener
busi strong posit benefit grow
demand emerg market
oclin data drug-elut stent altern
therapi put crimp percutan coronari
procedur medic therapi coronari bypass
gain favor
oabbott face uphil battl molecular
diagnost arena must go head-to-head
market leader roch along energet
competitor like
oslow growth fall birth rate china offer
abbott nutrit
segment could damp nutrit firm
final overcam regulatori chang china
drag growth
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
larg acquisit st jude medic aler
abbott enjoy less financi flexibl
time period remain steadi enough meet debt
oblig continu rais dividend
sale vision-car busi purchas st jude
abbott debt/ebitda hover around time
end sinc manag brought
debt level closer time end
expect debt/ebitda fall time
remain comfort abbott estim interest
coverag ebitda/interest time
coverag rise ensu year
abbott nutrit unit seem larg impervi
econom cycl think addit st jude increas
abbott exposur vagari cardiac product cycl
clinic trial reimburs issu accordingli
peg abbott uncertainti medium like compani
involv medic technolog abbott vulner
threat revolutionari innov rival
particularli issu medic devic diagnost
busi disrupt technolog often emerg
despit abbott recent effort better insul
recal like infant formula recal china
risk product qualiti issu recal remain
damag firm brand relationship medic
profession hospit custom payer
pressur furthermor hospit trend toward bundl
multilin contract expand beyond cardiac therapeut
area abbott could find disadvantag compar
key rival johnson
johnson final abbott oper scrutini
 food drug administr well regulatori
agenc oversea lead delay product
approv product
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
ceo/chairman board/
repres date owner name posit common share held report holder issuer
american fund invmt co amer
american fund growth fund amer
legal gener
share
fund
share
fund
overal rate abbott stewardship standard
compani made impress purchas
past decad includ purchas
billion brought humira sever
recent acquisit piram st jude
medic remain promis yet fulli match
purchas price remain skeptic acquisit
aler point-of-car diagnost seem
add compel valu abbott technolog
distribut bargain posit proprietari
pharma product spun expect
manag new focu remain busi
result greater effici profit
watch care see abbott abl realiz
potenti acquisit made avoid less
mile white soon step ceo role
held sinc abbott cusp first major
manag chang two decad robert ford set
take ceo white remain chairman
board point expect signific
chang strateg focu ford
abbott sinc bring wide-rang experi
across differ function divis nonetheless one
hallmark white tenur raft activ
suggest level comfort kind financi
engin perspect though anticip
abbott continu engag level
order augment intern innov curiou
prospect strateg acquisit technolog
ford
board strike us bit unwieldi
execut publicli trade firm chicago area
particularli pleas see stark former ceo
st jude join board expect experi
independ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
lead st jude ramp innov could posit
influenc abbott said think room
improv compens polici -- move away
benchmark involv adjust earn per share
ebit measur focus return invest
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
consid larg type market libr price
advantag competit cgm product
anticip could difficult unseat
libr leader type market
final also eager see abbott portico
transcathet aortic valv launch
regulatori approv expect mid-year
continu hold temper expect product
portico fourth market yet gain
substanti market share europ first receiv
regulatori approv late believ rival boston
scientif roll-out lotu tavr devic current
underway may provid view easili
late entrant shift competit landscap howev
think boston lotu product offer technolog
advantag portico includ genuin abil
reposit product perman deploy
mechan expans captur practition
attent reason think boston launch
experi could amount best-cas scenario may
reach abbott
abbott lab deliv strong third-quart result
expect oct
abbott lab post third-quart result held
surpris firm track close full-year
project result hold steadi
fair valu estim see littl shift view abbott
solid top line increas organ
constant currenc basi fuel renew strength
establish pharmaceut adopt new product
medic devic like firm also kept tight
control expens quarter whittl
interest payment pay debt
expect key growth driver seen third quarter
continu power robust perform
particular new alin core diagnost
system recent receiv fda approv base abbott
signific instal base well alin
grown outsid anticip strong uptak
domest also think mitraclip sustain double-
digit growth thank indic expans
cover function mitral regurgit recent
three-year data outcom anticip medicar
reimburs decis could goos demand
second half though expect abbott enjoy
signific head start edward lifesci pascal
devic nevertheless remain optimist pascal
abil eat mitraclip share europ longer
term base deliver eas use
also favor freestyl libr continu
glucos monitor next-gen version anticip
launch near term reimburs spread
adopt remain robust think abbott opportun
significantli penetr type diabet market
also pleas see abbott pursu collabor
sanofi tandem insulin pump technolog
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
